Defining Success in IBD: Treat-to-Target
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
The Future of Biologic Treatment in IBD: What’s on the Horizon
Michael Dolinger, MD, MBA
David T. Rubin, MD
Setting the Stage: Why Rethinking IBD Care Matters Now
Targeting IL-23 Pathways: Evolving Biologic Strategies in IBD
Navigating IBD Guidelines: What Clinicians Need to Know Now
The Evolving Role of Small Molecules in IBD Care
IBD in Focus: A Case-Based Approach to Diagnosis and Assessment
Pathophysiology of IBD: The War Within
IBD Beyond Symptoms: What Community GIs Need to Know
Beyond Biology: Environmental and Lifestyle Influences in IBD
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Severity Assessment: Can You Pin the Stage on the Patient?
Jennifer Geremia, PA-C
Brooke Hodnick, PA-C, MPAS
Treat-to-Target: Are We There Yet?
Kimberly D. Orleck, PA-C
Case Review: Targets Are Met—Can You Stick the Landing?
David Rubin, MD
Switching Strategies: Switch or Stay—What’s Your Call?
Loading...
We're glad to see you're enjoying Crohn's Colitis Professional… but how about a more personalized experience?
Press cancel to remain on Crohn's Colitis Professional. Press the link below or the continue button to keep going.